X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (73) 73
humans (71) 71
index medicus (61) 61
middle aged (58) 58
female (54) 54
adult (53) 53
male (50) 50
aged (46) 46
cancer (45) 45
hematology, oncology and palliative medicine (32) 32
treatment outcome (32) 32
chemotherapy (31) 31
research (28) 28
metastasis (26) 26
disease-free survival (25) 25
oncology, experimental (25) 25
tumors (24) 24
clinical trials (22) 22
sarcoma (21) 21
survival (21) 21
antineoplastic combined chemotherapy protocols - therapeutic use (20) 20
sarcoma - drug therapy (20) 20
care and treatment (18) 18
soft tissue sarcoma (17) 17
adolescent (16) 16
aged, 80 and over (15) 15
prognosis (15) 15
drug therapy (14) 14
kaplan-meier estimate (14) 14
young adult (14) 14
antineoplastic agents - therapeutic use (13) 13
antineoplastic combined chemotherapy protocols - adverse effects (13) 13
drug administration schedule (13) 13
doxorubicin (11) 11
europe (11) 11
inhibitor (11) 11
maximum tolerated dose (11) 11
soft tissue neoplasms - drug therapy (11) 11
analysis (10) 10
antineoplastic agents - administration & dosage (10) 10
dose-response relationship, drug (10) 10
pazopanib (10) 10
prognostic-factors (10) 10
sarcoma - mortality (10) 10
solid tumors (10) 10
trial (10) 10
efficacy (9) 9
neoplasm staging (9) 9
physics (9) 9
safety (9) 9
soft tissue neoplasms - mortality (9) 9
anthracyclines (8) 8
breast cancer (8) 8
docetaxel (8) 8
metastases (8) 8
patients (8) 8
pyrimidines - therapeutic use (8) 8
retrospective studies (8) 8
sulfonamides - therapeutic use (8) 8
antimitotic agents (7) 7
antineoplastic agents (7) 7
disease progression (7) 7
european organization (7) 7
neoadjuvant chemotherapy (7) 7
neoplasm metastasis (7) 7
neoplasms - drug therapy (7) 7
protein kinase inhibitors - therapeutic use (7) 7
sarcoma - pathology (7) 7
survival analysis (7) 7
survival rate (7) 7
time factors (7) 7
angiogenesis inhibitors - therapeutic use (6) 6
antineoplastic agents - adverse effects (6) 6
antineoplastic combined chemotherapy protocols - pharmacokinetics (6) 6
breast neoplasms - drug therapy (6) 6
crizotinib (6) 6
deoxycytidine - administration & dosage (6) 6
deoxycytidine - analogs & derivatives (6) 6
electric circuits or apparatus specially designed for use inequipment for killing, stunning, or guiding living beings (6) 6
electric techniques not otherwise provided for (6) 6
electricity (6) 6
eortc (6) 6
follow-up studies (6) 6
measuring (6) 6
measuring electric variables (6) 6
measuring magnetic variables (6) 6
medical research (6) 6
product development (6) 6
proportional hazards models (6) 6
prospective studies (6) 6
risk factors (6) 6
soft tissue neoplasms - pathology (6) 6
testing (6) 6
alarm systems (5) 5
angiogenesis (5) 5
breast neoplasms - pathology (5) 5
cancer patients (5) 5
cisplatin - administration & dosage (5) 5
classification (5) 5
clinical-trials (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, ISSN 1470-2045, 2012, Volume 13, Issue 10, pp. 1045 - 1054
Journal Article
Lancet Oncology, ISSN 1470-2045, 2014, Volume 15, Issue 4, pp. 415 - 423
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9829, pp. 1879 - 1886
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2012, Volume 30, Issue 10, pp. 1107 - 1113
Journal Article
Lancet Oncology, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 76 - 86
Summary Background Patients with muscle-invasive urothelial carcinoma of the bladder have poor survival after cystectomy. The EORTC 30994 trial aimed to... 
Hematology, Oncology and Palliative Medicine | ADJUVANT CHEMOTHERAPY | PLUS CISPLATIN | METAANALYSIS | NEOADJUVANT CHEMOTHERAPY | ONCOLOGY | DOXORUBICIN | METHOTREXATE | VINBLASTINE | CANCER | GEMCITABINE | Lymph Node Excision | Cystectomy - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma - mortality | Male | Vinblastine - administration & dosage | Cystectomy - adverse effects | Urothelium - pathology | Cisplatin - administration & dosage | Time Factors | Urinary Bladder Neoplasms - pathology | Female | Chemotherapy, Adjuvant | Carcinoma - pathology | Doxorubicin - administration & dosage | Carcinoma - drug therapy | Urinary Bladder Neoplasms - mortality | Drug Administration Schedule | Time-to-Treatment | Carcinoma - surgery | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Urinary Bladder Neoplasms - drug therapy | Urinary Bladder Neoplasms - surgery | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Methotrexate - administration & dosage | Urothelium - surgery | Neoplasm Staging | Urothelium - drug effects | Deoxycytidine - analogs & derivatives | Care and treatment | Chemotherapy | Carcinoma | Hospitals | Cancer
Journal Article
European Urology, ISSN 0302-2838, 2012, Volume 63, Issue 3, pp. 462 - 472
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 19, pp. 1789 - 1801
A blinded trial involving patients with resected stage III melanoma showed that adjuvant pembrolizumab every 3 weeks for a year was associated with a 1-year... 
HIGH-RISK MELANOMA | SURVIVAL | MEDICINE, GENERAL & INTERNAL | ANTI-PD-1 THERAPY | EORTC 18952 | TUMOR BURDEN | CUTANEOUS MELANOMA | PHASE-3 TRIAL | PEGYLATED INTERFERON-ALPHA-2B | NODE-POSITIVE MELANOMA | IPILIMUMAB | Skin Neoplasms - drug therapy | Humans | Middle Aged | Male | Adjuvants, Immunologic - adverse effects | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Adjuvants, Immunologic - therapeutic use | Skin Neoplasms - surgery | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Survival Rate | Disease-Free Survival | B7-H1 Antigen - antagonists & inhibitors | Melanoma - drug therapy | Intention to Treat Analysis | Quality of Life | Aged | B7-H1 Antigen - analysis | Infusions, Intravenous | Melanoma - surgery | Neoplasm Staging | Melanoma - mortality | Diagnosis | Drug therapy | Patients | Health aspects | Melanoma | Medical research | Lymphatic system | Risk groups | PD-1 protein | Committees | Metastasis | Survival | Skin cancer | Pembrolizumab | Hospitals | Motivation | PD-L1 protein | Myositis | Death | Mutation | Tumors | Cancer | Index Medicus | Abridged Index Medicus | Placebos | Placebos (Medicine) | Adjuvant treatment of cancer | Tractament adjuvant del càncer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 11, pp. 1045 - 1052
Journal Article
Journal Article
Journal Article